VA opens psychedelic therapy centers for veteran PTSD and chronic pain

What it does

This bill directs the VA to establish at least five centers of excellence across the country to research and treat veterans using psychedelic and dissociative drugs—including psilocybin, MDMA, ketamine, and ibogaine—for conditions like PTSD, depression, chronic pain, and substance use disorder. The centers must meet high scientific standards, partner with medical schools, and report annually to Congress on their findings; $30 million per year is authorized for the effort.

Why we flagged it

The bill's core mechanism is a public health initiative—establishing VA research and treatment centers for emerging psychedelic therapies targeting veteran mental health and chronic pain. It is not a commemorative, appropriations, or deregulatory measure; it is a targeted expansion of VA clinical capacity in a specific therapeutic domain.

What the text implies

• The bill grants the Under Secretary for Health broad discretion to designate 'such other therapies' and 'such other conditions' beyond those listed, potentially enabling rapid expansion of the program without additional legislative action.
• Peer review panel is explicitly exempted from the Federal Advisory Committee Act (FACA), reducing transparency and public participation in the selection of which VA facilities become centers—a departure from standard federal advisory governance.
• The bill authorizes $30M annually but also permits the Under Secretary to allocate additional funds from existing VA medical services and research budgets, potentially redirecting resources from other VA programs without explicit appropriation.
• No explicit sunset clause or periodic reauthorization requirement; once established, centers operate indefinitely subject only to annual reporting, creating a permanent new VA program structure.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Veterans with treatment-resistant PTSD, depression, chronic pain, and substance use disorders gain access to emerging evidence-based therapies (MDMA-assisted therapy, psilocybin-assisted therapy, ketamine) that show clinical promise in peer-reviewed research. The bill establishes rigorous peer-review standards, requires academic partnerships, mandates veteran input via advisory committees, and creates transparency through annual congressional reporting—all safeguards against reckless deployment.

Who stands to gain

• VA medical facilities selected as centers of excellence (infrastructure, staffing, research funding)
• Academic medical schools and psychiatry/social work programs affiliated with designated VA facilitie
• Biotech and pharmaceutical companies developing psychedelic-assisted therapies (potential market val

Named in the bill

Department of Veterans Affairs, Secretary of Veterans Affairs, Under Secretary for Health, Senate Committee on Veterans' Affairs, House Committee on Veterans' Affairs, Accredited medical schools, Accredited schools of psychiatry, Accredited schools of social work

Where it stands

1 cosponsor: 1 Republicans.

• Mar 9, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 9, 2026 — Referred to Senate Committee on Veterans' Affairs · Congress.gov: “Read twice and referred to the Committee on Veterans' Affairs”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.